Peter Kießling

2.4k total citations
40 papers, 1.9k citations indexed

About

Peter Kießling is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Peter Kießling has authored 40 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 13 papers in Genetics and 12 papers in Immunology. Recurrent topics in Peter Kießling's work include Platelet Disorders and Treatments (10 papers), Immunodeficiency and Autoimmune Disorders (10 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (10 papers). Peter Kießling is often cited by papers focused on Platelet Disorders and Treatments (10 papers), Immunodeficiency and Autoimmune Disorders (10 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (10 papers). Peter Kießling collaborates with scholars based in Germany, United States and Poland. Peter Kießling's co-authors include Uwe Nicolay, Melvin Berger, Hans D. Ochs, Sudhir Gupta, Ann Gardulf, Stefan Haag, Stephen Jolles, Againdra K. Bewtra, Timothy Craig and Robyn J. Levy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Peter Kießling

40 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Kießling Germany	19	972	724	583	324	307	40	1.9k
Alessandra Stacchini Italy	26	638 0.7×	495 0.7×	637 1.1×	90 0.3×	162 0.5×	76	1.9k
Kirsten van Lom Netherlands	25	253 0.3×	579 0.8×	427 0.7×	75 0.2×	153 0.5×	47	1.5k
Maria Christina Cox Italy	30	430 0.4×	1.2k 1.7×	516 0.9×	66 0.2×	198 0.6×	111	2.8k
Richard Ghalie United States	23	359 0.4×	406 0.6×	204 0.3×	56 0.2×	143 0.5×	68	1.6k
Philippe Quittet France	22	456 0.5×	750 1.0×	265 0.5×	70 0.2×	71 0.2×	49	1.6k
Annalisa Chiarenza Italy	20	604 0.6×	436 0.6×	630 1.1×	92 0.3×	119 0.4×	84	2.4k
Debra Saxe United States	20	204 0.2×	458 0.6×	244 0.4×	231 0.7×	60 0.2×	45	1.4k
Peter D. Emanuel United States	27	571 0.6×	900 1.2×	578 1.0×	118 0.4×	108 0.4×	72	2.0k
Thierry Lavabre‐Bertrand France	19	309 0.3×	318 0.4×	237 0.4×	83 0.3×	149 0.5×	59	1.4k
Kamil R. Kranc United Kingdom	20	446 0.5×	479 0.7×	187 0.3×	186 0.6×	71 0.2×	41	2.1k

Countries citing papers authored by Peter Kießling

Since Specialization

Citations

This map shows the geographic impact of Peter Kießling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kießling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kießling more than expected).

Fields of papers citing papers by Peter Kießling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Kießling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kießling. The network helps show where Peter Kießling may publish in the future.

Co-authorship network of co-authors of Peter Kießling

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Kießling. A scholar is included among the top collaborators of Peter Kießling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Kießling. Peter Kießling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bril, Vera, Johannes Lampe, Nichola Cooper, Peter Kießling, & Ann Gardulf. (2024). Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. Journal of Comparative Effectiveness Research. 13(9). e230171–e230171. 3 indexed citations

Hoepner, Robert, Mathias Abegg, Christopher Linington, et al.. (2022). Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis. Neurology Neuroimmunology & Neuroinflammation. 9(2). 18 indexed citations

Bril, Vera, Michael Benatar, Henning Andersen, et al.. (2020). Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis. Neurology. 96(6). e853–e865. 113 indexed citations

Peter, Hans‐Hartmut, Hans D. Ochs, Charlotte Cunningham‐Rundles, et al.. (2020). Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. Journal of Allergy and Clinical Immunology. 146(3). 479–491.e5. 82 indexed citations

Kießling, Peter, Rocío Lledó‐García, Shikiko Watanabe, et al.. (2017). The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Science Translational Medicine. 9(414). 152 indexed citations

Robak, Tadeusz, Isidro Jarque, Peter Kießling, et al.. (2017). Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis. Blood. 130. 15–15. 11 indexed citations

Berger, Melvin, Mikhail Rojavin, Peter Kießling, & O. Zenker. (2011). Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clinical Immunology. 139(2). 133–141. 80 indexed citations

Schulze, Thomas G., et al.. (2010). How the green alga Chlamydomonas reinhardtii keeps time. PROTOPLASMA. 244(1-4). 3–14. 37 indexed citations

Craig, Timothy, Richard L. Wasserman, Robyn J. Levy, et al.. (2010). Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary Angioedema. Journal of Clinical Immunology. 30(6). 823–829. 37 indexed citations

10.

Wasserman, Richard L., Robyn J. Levy, Againdra K. Bewtra, et al.. (2010). Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Annals of Allergy Asthma & Immunology. 106(1). 62–68. 13 indexed citations

11.

Church, Joseph A., Michael Borte, Hassan Taki, et al.. (2009). Efficacy and Safety of Privigen in Children and Adolescents With Primary Immunodeficiency. Pediatric Asthma Allergy & Immunology. 22(2). 53–62. 18 indexed citations

12.

Wasserman, Richard L., Againdra K. Bewtra, James N. Moy, et al.. (2009). C1 Esterase Inhibitor Concentrate (C1-INH) for the Treatment of Acute Attacks of Hereditary Angioedema: Interim Results of an Ongoing, Prospective, Open Label Study in North America after 640 attacks (I.M.P.A.C.T.2). Journal of Allergy and Clinical Immunology. 123(2). S99–S99. 3 indexed citations

13.

Nicolay, Uwe, Peter Kießling, Melvin Berger, et al.. (2006). Health-Related Quality of Life and Treatment Satisfaction in North American Patients with Primary Immunedeficiency Diseases Receiving Subcutaneous IgG Self-Infusions at Home. Journal of Clinical Immunology. 26(1). 65–72. 162 indexed citations

14.

Ochs, Hans D., et al.. (2006). Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases. Journal of Clinical Immunology. 26(3). 265–273. 198 indexed citations

15.

Gardulf, Ann, Uwe Nicolay, Òscar Asensio, et al.. (2006). Rapid Subcutaneous IgG Replacement Therapy is Effective and Safe in Children and Adults with Primary Immunodeficiencies—A Prospective, Multi-National Study. Journal of Clinical Immunology. 26(2). 177–185. 154 indexed citations

16.

Gardulf, Ann, Uwe Nicolay, Òscar Asensio, et al.. (2004). Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. Journal of Allergy and Clinical Immunology. 114(4). 936–942. 209 indexed citations

17.

Praus, Michaela, et al.. (2004). Phase I Comparability of Recombinant Human Albumin and Human Serum Albumin. The Journal of Clinical Pharmacology. 45(1). 57–67. 48 indexed citations

18.

Remedios, Cristobal G. dos, Desirée A. Berry, Joëlle V. F. Coumans, et al.. (1996). Different electrophoretic techniques produce conflicting data in the analysis of myocardial samples from dilated cardiomyopathy patients: Protein levels do not necessarily reflect mRNA levels. Electrophoresis. 17(1). 235–238. 7 indexed citations

19.

Kießling, Peter, Werner Jahn, G. Maier, Bernhard Polzar, & Hans Georg Mannherz. (1995). Purification and Characterization of Subtilisin Cleaved Actin Lacking the Segment of Residues 43-47 in the DNase I Binding Loop. Biochemistry. 34(45). 14834–14842. 11 indexed citations

20.

Hambly, Brett D., Peter Kießling, & C.G. dos Remedios. (1994). Evidence for an F-Actin Like Conformation in the ACTIN:DNASE I Complex. Advances in experimental medicine and biology. 358. 25–34. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact